PL1691892T3 - Odporna na fizyczne manipulowanie, współwytłaczana postać dawkowania zawierająca środek aktywny i środek przeciwdziałający oraz sposób wytwarzania tej postaci - Google Patents

Odporna na fizyczne manipulowanie, współwytłaczana postać dawkowania zawierająca środek aktywny i środek przeciwdziałający oraz sposób wytwarzania tej postaci

Info

Publication number
PL1691892T3
PL1691892T3 PL04813471T PL04813471T PL1691892T3 PL 1691892 T3 PL1691892 T3 PL 1691892T3 PL 04813471 T PL04813471 T PL 04813471T PL 04813471 T PL04813471 T PL 04813471T PL 1691892 T3 PL1691892 T3 PL 1691892T3
Authority
PL
Poland
Prior art keywords
dosage form
agent
form containing
making same
tamper resistant
Prior art date
Application number
PL04813471T
Other languages
English (en)
Polish (pl)
Inventor
Robert P Flath
John K Masselink
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PL1691892T3 publication Critical patent/PL1691892T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04813471T 2003-12-09 2004-12-08 Odporna na fizyczne manipulowanie, współwytłaczana postać dawkowania zawierająca środek aktywny i środek przeciwdziałający oraz sposób wytwarzania tej postaci PL1691892T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52855003P 2003-12-09 2003-12-09
EP04813471A EP1691892B1 (en) 2003-12-09 2004-12-08 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
PCT/US2004/041154 WO2005055981A2 (en) 2003-12-09 2004-12-08 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same

Publications (1)

Publication Number Publication Date
PL1691892T3 true PL1691892T3 (pl) 2007-07-31

Family

ID=34676850

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04813471T PL1691892T3 (pl) 2003-12-09 2004-12-08 Odporna na fizyczne manipulowanie, współwytłaczana postać dawkowania zawierająca środek aktywny i środek przeciwdziałający oraz sposób wytwarzania tej postaci

Country Status (13)

Country Link
US (1) US20070269505A1 (enExample)
EP (1) EP1691892B1 (enExample)
JP (3) JP4917893B2 (enExample)
AT (1) ATE355103T1 (enExample)
CA (1) CA2548834C (enExample)
CY (1) CY1106600T1 (enExample)
DE (1) DE602004005076T2 (enExample)
DK (1) DK1691892T3 (enExample)
ES (1) ES2281851T3 (enExample)
PL (1) PL1691892T3 (enExample)
PT (1) PT1691892E (enExample)
SI (1) SI1691892T1 (enExample)
WO (1) WO2005055981A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
CA2519556C (en) 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20070269505A1 (en) * 2003-12-09 2007-11-22 Flath Robert P Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
CA2557839C (en) 2004-03-30 2011-05-10 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US9522188B2 (en) 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
EP2719378B1 (en) * 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
CN101511337B (zh) 2006-07-21 2013-12-11 生物递送科学国际公司 吸收增强的经粘膜递送装置
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ES2692437T3 (es) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
CA2709992A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Abuse resistant pharmaceutical compositions of opiod agonists
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
CA2709903A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Oral opioid compositions with opioid antagonist
AU2015200313B2 (en) * 2007-12-17 2016-12-01 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008343267A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
KR101616246B1 (ko) * 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
CN102209540A (zh) * 2008-11-11 2011-10-05 塔加西普特公司 使用α7-选择性配体的治疗方法
BRPI0917608B8 (pt) 2008-12-12 2021-05-25 Paladin Labs Inc formulação de droga oral para a redução de potencial efeito abusivo, processo para a fabricação de uma formulação de droga e seu uso
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
EP2243470A1 (de) * 2009-04-22 2010-10-27 Dr. Suwelack Skin & Health Care AG Gefriergetrockneter beschichteter Formkörper
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
PE20120631A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
ITVR20110069A1 (it) * 2011-04-06 2012-10-07 Eurocoating S P A Metodo per la realizzazione di un biomateriale a base di calcio fosfato sotto forma di granuli e/o loro aggregati e biomateriale ottenuto con lo stesso
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
PE20141650A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
JP6158810B2 (ja) 2011-08-18 2017-07-05 バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
ES2583132T3 (es) * 2011-09-16 2016-09-19 Purdue Pharma L.P. Formulaciones de liberación inmediata resistentes a alteración
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
RS57913B1 (sr) 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2835246A1 (en) * 2013-08-05 2015-02-11 Ansa Termoplastici S.r.l. Method and apparatus for producing extruded plastic elements
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5492692A (en) * 1993-08-17 1996-02-20 University Of Kentucky Research Foundation Coated products with potent anti-HIV and antimicrobial properties
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6063405A (en) * 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
IN183097B (enExample) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
ES2539904T3 (es) * 2000-02-08 2015-07-07 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
ATE293439T1 (de) * 2000-12-07 2005-05-15 Warner Lambert Co Verfahren und system zur gleichmä igen arzneistoffabgabe
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
CA2499550C (en) * 2002-09-20 2013-10-15 Alpharma, Inc. Sequestering subunit and related compositions and methods
CA2519556C (en) * 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
US20070269505A1 (en) * 2003-12-09 2007-11-22 Flath Robert P Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same

Also Published As

Publication number Publication date
PT1691892E (pt) 2007-05-31
JP2007513960A (ja) 2007-05-31
DE602004005076D1 (de) 2007-04-12
DE602004005076T2 (de) 2007-11-15
JP5473958B2 (ja) 2014-04-16
US20070269505A1 (en) 2007-11-22
CA2548834A1 (en) 2005-06-23
CA2548834C (en) 2009-08-11
ES2281851T3 (es) 2007-10-01
CY1106600T1 (el) 2012-01-25
WO2005055981A3 (en) 2005-08-11
WO2005055981A2 (en) 2005-06-23
JP2011126895A (ja) 2011-06-30
ATE355103T1 (de) 2006-03-15
SI1691892T1 (sl) 2007-08-31
DK1691892T3 (da) 2007-06-25
EP1691892A2 (en) 2006-08-23
JP4917893B2 (ja) 2012-04-18
EP1691892B1 (en) 2007-02-28
JP2012082214A (ja) 2012-04-26

Similar Documents

Publication Publication Date Title
SI1691892T1 (sl) Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave
IL178175A0 (en) Tamper resistant dosage form comprising an adsorbent and an adverse agent
WO2004093819A3 (en) Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
WO2005107726A3 (en) Method for the treatment of back pain
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
MY161079A (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
Raffa et al. Opioid receptors and acetaminophen (paracetamol)
CY1109264T1 (el) Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου
ATE506065T1 (de) Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen
DE60236496D1 (de) Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
WO2003094921A3 (de) Verwendung von hemmern der egfr-vermittelten signaltransduktion zur behandlung von gutartiger prostatahyperplasie (bph)/prostatahypertrophie
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
WO2005009340A3 (en) Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
ATE287265T1 (de) Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz
NO20035038D0 (no) Forhindring av avhengighet ved smertebehandling
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
WO2005037318A3 (en) Treatment of arthritic conditions, chronic inflammation or pain